Basel, Switzerland-February 12, 2018-The Children’s Emergency Hospital "Louis Turcanu" (Spitalul Clinic de Urgenta pentru Copii „Louis Èurcanu”), in TimiÈoara, is the first hospital in Clinerion’s PRS network which specializes in pediatric care, opening up PRS to more expert research in the field. The "Louis Turcanu" hospital is the leading pediatric healthcare facility in Western Romania. Founded in 1903, it offers a variety of professional activities covering the full range of pediatric specialties. It has more than 500 beds and 8 principal investigators running more than 20 clinical studies per year. By joining Clinerion’s PRS platform, the "Louis Turcanu" hospital will benefit from improved access to leading-edge sponsored clinical trials run by international pharmaceutical companies and contract research organizations. The hospital’s investigators will reap huge time savings during site evaluation and when screening for eligible patients for studies. Their patients will gain early access to innovative medication and more options for treatments. They will also benefit from PRS’ ability to query their own patient database with complex criteria via a simple web interface without compromising patient privacy. “Our hospital has a long history of leadership in children’s health and we continue to contribute to the development of pediatric medicine by running studies for clinical research. PRS offers us exposure to more research which is innovative and international in scale,” says Dr. Adam Ovidiu, Manager of Louis Turcanu. “The beauty of Clinerion’s network is that we are able to propose trial sites around the world and with a plethora of specializations to sponsors. We are thrilled to add the Children’s Emergency Hospital "Louis Turcanu" and its expert pediatric clinicians to PRS,” says Ulf Claesson, CEO of Clinerion. About Clinerion Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's PRS accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website: www.clinerion.com Clinerion’s PRS: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.